Compare Abeona Therapeutics Inc (ABEO) vs iShares MSCI Germany (DAX) (EWG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs iShares MSCI Germany (DAX) — how do they compare? Abeona Therapeutics Inc trades at $6.76 (market cap $373.32M), while iShares MSCI Germany (DAX) trades at $41.33. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, iShares MSCI Germany (DAX) nearer its low. Which is the better fit depends on your goals.
| ABEO | EWG | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $7.23 | $44.56 |
52-Week Low | $4.17 | $38.08 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
EWG is trading at $42.66, up 0.83% with a bullish technical signal from moving averages. The stock shows strong momentum indicators but RSI suggests potential overbought conditions. Recent European market strength and German economic reforms provide positive backdrop. Dividend of $0.83 scheduled for June 2026 indicates shareholder returns commitment.
Outlook remains positive with European equity momentum and potential short-squeeze dynamics. Key risks include ECB rate hikes impacting growth sectors and German industrial employment concerns. Investment opportunity lies in European market rotation and cyclical sector strength, though valuation metrics require monitoring given limited fundamental data availability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About iShares MSCI Germany (DAX)
EWG is a country-specific ETF that tracks the performance of the German equity market. It provides exposure to large and mid-sized companies in Germany across key sectors like industrials and financials, with top holdings such as SAP, Siemens, and Allianz.
Read more on EWG →
